Veronika Sherwood

Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor

David W. Fry, Alexander J. Bridges, William A. Denny et al. · Proceedings of the National Academy of Sciences · 1998 · 417 citations

Drug Target, Cell Growth, Chemical Biology +21

Tyrosine Kinase Inhibitors. 18. 6-Substituted 4-Anilinoquinazolines and 4-Anilinopyrido[3,4-<i>d</i>]pyrimidines as Soluble, Irreversible Inhibitors of the Epidermal Growth Factor Receptor

Jeff B. Smaill, H. D. Hollis Showalter, Hairong Zhou et al. · Journal of Medicinal Chemistry · 2000 · 89 citations · Full text

Anticancer efficacy of the irreversible EGFr tyrosine kinase inhibitor PD 0169414 against human tumor xenografts

Patrick W. Vincent, Alex Bridges, Donald J. Dykes et al. · Cancer Chemotherapy and Pharmacology · 2000 · 48 citations

Oncology, Human Tumor Xenografts, Medicine +9

Tyrosine Kinase Inhibitors. 17. Irreversible Inhibitors of the Epidermal Growth Factor Receptor:  4-(Phenylamino)quinazoline- and 4-(Phenylamino)pyrido[3,2-<i>d</i>]pyrimidine-6-acrylamides Bearing Additional Solubilizing Functions.

Jeff B. Smaill, Gordon W. Rewcastle, Alexander J. Bridges et al. · Journal of Medicinal Chemistry · 2000 · 15 citations

Altmetric Attention Score, Pharmacotherapy, Dermatology +19